Results demonstrate that systemic in vivo delivery of Tamoxifen is effective in amplifying endogenously expressed levels of immunotherapeutic targets such as α-Lactalbumin selectively on hormone receptor positive breast tumors, with no deleterious bystander effect on protein expression in normal breast tissue. This evidence concerns the gene NR4A1 and breast neoplasm.